Is It Safe to Take Ibuprofen and Codeine?

Profen-profen sustained-release tablets, the indications are mainly used for moderate pain analgesia caused by a variety of reasons, such as: cancer pain, postoperative pain, joint pain, neuralgia, muscle pain, migraine, headache, dysmenorrhea , Toothache, etc.

Drug Name: Profenine sustained release tablets

Drug type: Prescription drugs, medicines for medical workers' injuries

Ingredients of ibuprofen sustained-release tablets

This product is a compound preparation, and its components are: each tablet contains ibuprofen 0.2g and codeine phosphate 13mg.

Properties of ibuprofen sustained-release tablets

This product is a pink film-coated double-layered tablet. After removing the coating, it is white or slightly yellow.

Indications of ibuprofen sustained-release tablets

It is mainly used for moderate pain analgesia caused by various reasons, such as cancer pain, postoperative pain, joint pain, neuralgia, muscle pain, migraine, headache, dysmenorrhea, toothache and so on.

Profen codeine sustained release tablets specifications

Ibuprofen 0.2g, codeine phosphate 13mg

Profen-profen sustained-release tablets

Orally, swallow whole tablets, 2 to 4 tablets every 12 hours for adults.

Adverse effects of ibuprofen sustained-release tablets

May have gastrointestinal discomfort, occasional dizziness, nausea, vomiting, constipation, itchy skin and rash. Codeine phosphate: occasional fantasy; weak breathing: abnormal heart rate, etc.

Profen and Profen

1. Patients known to be allergic to this product.
2. Patients who have asthma, urticaria, or allergic reactions after taking aspirin or other non-steroidal anti-inflammatory drugs.
3 It is contraindicated in the treatment of perioperative pain in coronary artery bypass surgery (CABG).
4 Patients with a history of gastrointestinal bleeding or perforation after application of non-steroidal anti-inflammatory drugs.
5. Patients with active gastrointestinal ulcers / bleeding, or previous recurrent lesions / bleeds.
6. Patients with severe heart failure.
7. Bronchial asthma patients are disabled.
8. Banned for pregnant and lactating women.
9. Children under 12 years are disabled.

Proceedings of ibuprofen sustained-release tablets

1. Avoid combination with other non-steroidal anti-inflammatory drugs, including selective COX-2 inhibitors.
2. According to the need to control symptoms, using the lowest effective dose in the shortest treatment time can minimize adverse reactions.
3 Adverse reactions to gastrointestinal bleeding, ulcers, and perforations can occur at any time during treatment with all non-steroidal anti-inflammatory drugs, and the risks can be fatal. These adverse reactions may be accompanied by or without warning symptoms, regardless of whether the patient has a history of gastrointestinal adverse reactions or a history of severe gastrointestinal events. Patients with a previous history of gastrointestinal epilepsy (ulcerative colitis, Crohn's disease) should be cautious in using non-steroidal anti-inflammatory drugs to avoid worsening the condition. The drug should be discontinued when a patient experiences gastrointestinal bleeding or ulcers after taking the drug. The increased frequency of adverse reactions in elderly patients with non-steroidal anti-inflammatory drugs, especially gastrointestinal bleeding and perforation, can be fatal.
4 Clinical trials of a variety of COX-2 selective or non-selective NSAIDs for up to 3 years have shown that this product may increase the risk of serious cardiovascular thrombotic adverse events, myocardial infarction and stroke, and the risk may be fatal . All NSAIDs, including COX-2 selective or non-selective drugs, may have similar risks. Patients with cardiovascular disease or cardiovascular disease risk factors are at greater risk. Doctors and patients should be alert to the occurrence of such events, even if they have no previous cardiovascular symptoms. Patients should be informed of the symptoms and / or signs of severe cardiovascular safety and the steps to be taken if they occur.
Patients should be alert to symptoms and signs such as chest pain, shortness of breath, weakness, and vague speech, and should seek medical help immediately after any of these symptoms or signs occur.
5. As with all non-steroidal anti-inflammatory drugs (NSAIDs), this product can cause new hypertension or exacerbate existing hypertension symptoms, any of which can lead to an increased incidence of cardiovascular events. Non-steroidal anti-inflammatory drugs (NSAIDs) may be affected by patients taking thiazide or myelin diuretics, which may affect the efficacy of these drugs. Patients with hypertension should use NSAIDs, including this product, with caution. Blood pressure should be closely monitored during the beginning of the treatment and throughout the treatment.
6. Patients with a history of hypertension and / or heart failure (such as fluid retention and edema) should be used with caution.
7. NSAIDs, including this product, can cause fatal, serious skin adverse reactions, such as exfoliative dermatitis, Stevens Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN). These serious events can occur without warning. Patients should be informed of the symptoms and signs of severe skin reactions, and should be discontinued when the skin rash or other signs of an allergic reaction first appear.
8. Codeine phosphate: Long-term use can cause dependence, but its tendency is weaker than other morphine drugs.
9. Use with caution in patients with undiagnosed pain.
10 Do not overdose.
11. This product should be placed out of reach of children.

Ibuprofen sustained-release tablets for pregnant and lactating women

During pregnancy, the placenta can be passed through, which can cause fetal addiction, prolong the pregnancy, cause dystocia and prolonged labor, and cause respiratory depression in the newborn during delivery, which can be excreted from the milk. Banned for pregnant and lactating women.

Ibuprofen sustained-release tablets for children

Children under 12 are disabled.

Profenine Sustained-release Tablets

The elderly (especially those over 70 years old) can begin to use half the amount. If it is ineffective and well tolerated, it can be gradually increased to the effective amount, but should be closely monitored or as directed by a doctor.

Drug Interactions of Profenine Prolonged Release Tablets

1. When used with anticoagulants such as heparin and dicoumarin and platelet aggregation inhibitors, there is a risk of increased bleeding.
2. When used with furosemide, the latter's sodium excretion and hypotensive effect are weakened.
3 When used with verapamil and nifedipine, the blood concentration of this product increases.
4 This product can increase the blood concentration of digoxin. At the same time, pay attention to adjust the dose of digoxin.
5. This product can enhance the effect of anti-diabetic drugs (including oral hypoglycemic drugs).
6. This product can affect the antihypertensive effect of the latter when used with antihypertensive drugs.
7. Probenecid can reduce the excretion of this product, increase blood concentration, thereby increasing toxicity, so it should be reduced when used together.
8. This product can reduce the excretion of methotrexate, increase its blood concentration, and even reach the level of poisoning. Therefore, this product should not be used with medium or large dose methotrexate therapy.

Profen-profen Sustained-release tablets overdose

If you take too much or have serious adverse reactions, you should go to the hospital immediately.

Pharmacology and Toxicology

This product consists of ibuprofen and codeine phosphate. Ibuprofen is an anti-inflammatory analgesic. It inhibits the analgesic effect of inflammatory tissues of the pain source by inhibiting cyclooxygenase. Codeine phosphate is a central analgesic. The two have different mechanisms of action and the best Matching composition, play a synergistic effect of analgesia. Phosphoric acid in the bilayer tablet can be an immediate analgesic because of the immediate-release layer; ibuprofen is a slow-release layer and has a long-lasting analgesic effect. After taking the analgesic, the analgesic time is 30 minutes, the analgesic duration is about 12 hours, and the optimal analgesic time is about 4-7 hours.

Pharmacokinetics of ibuprofen sustained-release tablets

Various parameters of pharmacokinetics in the body after ibuprofen and codeine combined are still similar to those taken alone, and have no mutual effect. When codeine phosphate was administered orally at 60 mg, the peak concentration was 170.3 ng / ml, the peak time was 0.6 hours, the half-life was 4.5 hours, the elimination rate constant was 1.9 hours, and the area under the blood concentration time curve was 649 ng · h / ml. Excreted by the kidneys, mainly glutaric acid conjugates. The sustained-release ibuprofen of this product has been studied by human bioavailability. When taken orally at 600 mg, the peak concentration is 16.73 mg / L, the peak time is 3.0 hours, the half-life is 5.3 hours, the elimination rate constant is 1.14 hours, and the blood concentration The area under the time curve was 176 mg.h / L. It is reported in the literature that ibuprofen is metabolized in the liver, 60 to 90% is excreted by the kidney through the urine, and 100% is excreted in 24 hours, of which about 1% is the original form, and some are excreted with feces.

Profenine Sustained-release Tablets Storage

Protected from light and sealed.

Profenine sustained release tablets packaging

10 pcs / board × 1 board / box, 10 pcs / board × 2 board / box

Expiry date of ibuprofen sustained-release tablets

24 months

Proceeding Standards

State Food and Drug Administration National Drug Standard WS _1- (X-214) -2004Z ^[1]